Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W, Mangioni C, Landoni F, D'Incalci M

Flow cytometric analysis of DNA content in human ovarian cancers.

Br J Cancer 1989; 45-50. doi: 10.1038/bjc.1989.217

Foster BJ, Clagett-Carr K, Marsoni S, Simon R, Leyland-Jones B

Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?

Cancer Treat Rep 1986; 1003-14.

Bizzi A, Codegoni AM, Landoni F, Marelli G, Marsoni S, Spina AM, Torri W, Mangioni C

Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.

Cancer Res 1988; 6222-6.

Weiss RB, Grillo-López AJ, Marsoni S, Posada JG, Hess F, Ross BJ

Amsacrine-associated cardiotoxicity: an analysis of 82 cases.

J Clin Oncol 1986; 918-28. doi: 10.1200/JCO.1986.4.6.918

Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R

Therapeutic response in phase I trials of antineoplastic agents.

Cancer Treat Rep 1986; 1105-15.

Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE

Clinical drug development: an analysis of phase II trials, 1970-1985.

Cancer Treat Rep 1987; 71-80.

Liberati A, Mangioni C, Bratina L, Carinelli G, Marsoni S, Parazzini F, Regallo M, Talamini R, Tognoni G

Process and outcome of care for patients with ovarian cancer.

Br Med J (Clin Res Ed) 1985; 1007-12. doi: 10.1136/bmj.291.6501.1007

Wittes RE, Marsoni S, Simon R, Leyland-Jones B

The phase II trial.

Cancer Treat Rep 1985; 1235-9.

Libretti A, Piazza E, Scanni A, Tomirotti M, Biraghi M, Scapaticci R, Bianchi C, Restelli G, Scarpazza G, Calzavara MP, Marsoni S, Morasca L

Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.

Cancer Treat Rep 1981; 171-2.

Ottolenghi I, Piazza E, Marsoni S, Trabattoni A, Natale N, Recchia M, Morasca L

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.

Eur J Cancer (1965) 1981; 365-6. doi: 10.1016/0014-2964(81)90129-8

Shoemaker DD, O'Dwyer PJ, Marsoni S, Plowman J, Davignon JP, Davis RD

Spiromustine: a new agent entering clinical trials.

Invest New Drugs 1983; 303-8. doi: 10.1007/BF00177413

O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD

Tiazofurin: a new antitumor agent.

Invest New Drugs 1984; 79-84. doi: 10.1007/BF00173791

O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S

Teniposide: a review of 12 years of experience.

Cancer Treat Rep 1984; 1455-66.

Pisoni MB, Libretti A, Piazza E, Vago G, Scapaticci R, Bianchi C, Tomirotti M, Scanni A, Calzavara MP, Cassani L, Scarpazza G, Marsoni S, Morasca L

Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.

Cancer Treat Rep 1981; 731-2.

Poster DS, Penta J, Marsoni S, Bruno S, Macdonald JS

Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.

Cancer Clin Trials 1980; 315-20.

Morasca L, Marsoni S, Pisoni MB, Piazza E, Vago G, Casali W, Cogo R, Bianchi C, Scapaticci R

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.

Cancer Chemother Pharmacol 1982; 209-10. doi: 10.1007/BF00254551

Ottolenghi L, Morasca L, Marsoni S, Piazza E, Soresi E, Libretti A, Garattini S

Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.

Biomedicine 1980; 123-7.

Piazza E, Donelli MG, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Morasca L

Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Cancer Treat Rep 1980; 845-54.

Alexanian AA, Scorpiglione N, Apolone G, Fossati R, Liberati A, Grilli R, Liberati MC, Marsoni S, Monferroni N, Mosconi P

Breast cancer surgery in 30 Italian general hospitals.

Eur J Surg Oncol 1993; 123-9.

Pater JL, Zee B, Myles J, Pignon JP, Milan C, Sahmoud T, Torri V, Marsoni S

A proposal for a new approach to intergroup cancer trials.

Eur J Cancer 1995; 1921-3. doi: 10.1016/0959-8049(95)00433-5

Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Viganò L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.

Ann Oncol 2000; 977-83. doi: 10.1023/a:1008302309734

Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.

Int J Radiat Oncol Biol Phys 2003; 78-92. doi: 10.1016/s0360-3016(02)03792-6

Della Bella S, Calcaterra F, Bacci M, Carenza C, Pandolfo C, Ferrazzi P, Uva P, Pagani M, Lodigiani C, Mavilio D

Pathologic up-regulation of TNFSF15-TNFRSF25 axis sustains endothelial dysfunction in unprovoked venous thromboembolism.

Cardiovasc Res 2020; 698-707. doi: 10.1093/cvr/cvz131

López-Tobón A, Villa CE, Cheroni C, Trattaro S, Caporale N, Conforti P, Iennaco R, Lachgar M, Rigoli MT, Marcó de la Cruz B, Lo Riso P, Tenderini E, Troglio F, De Simone M, Liste-Noya I, Macino G, Pagani M, Cattaneo E, Testa G

Human Cortical Organoids Expose a Differential Function of GSK3 on Cortical Neurogenesis.

Stem Cell Reports 2019; 847-861. doi: 10.1016/j.stemcr.2019.09.005

Alvisi G, Brummelman J, Puccio S, Mazza EM, Tomada EP, Losurdo A, Zanon V, Peano C, Colombo FS, Scarpa A, Alloisio M, Vasanthakumar A, Roychoudhuri R, Kallikourdis M, Pagani M, Lopci E, Novellis P, Blume J, Kallies A, Veronesi G, Lugli E

IRF4 instructs effector Treg differentiation and immune suppression in human cancer.

J Clin Invest 2020; 3137-3150. doi: 10.1172/JCI130426

Bonnal RJP, Rossetti G, Lugli E, De Simone M, Gruarin P, Brummelman J, Drufuca L, Passaro M, Bason R, Gervasoni F, Della Chiara G, D'Oria C, Martinovic M, Curti S, Ranzani V, Cordiglieri C, Alvisi G, Mazza EMC, Oliveto S, Silvestri Y, Carelli E, Mazzara S, Bosotti R, Sarnicola ML, Godano C, Bevilacqua V, Lorenzo M, Siena S, Bonoldi E, Sartore-Bianchi A, Amatu A, Veronesi G, Novellis P, Alloisio M, Giani A, Zucchini N, Opocher E, Ceretti AP, Mariani N, Biffo S, Prati D, Bardelli A, Geginat J, Lanzavecchia A, Abrignani S, Pagani M

Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression.

Nat Immunol 2021; 735-745. doi: 10.1038/s41590-021-00930-4

Frittoli E, Palamidessi A, Iannelli F, Zanardi F, Villa S, Barzaghi L, Abdo H, Cancila V, Beznoussenko GV, Della Chiara G, Pagani M, Malinverno C, Bhattacharya D, Pisati F, Yu W, Galimberti V, Bonizzi G, Martini E, Mironov AA, Gioia U, Ascione F, Li Q, Havas K, Magni S, Lavagnino Z, Pennacchio FA, Maiuri P, Caponi S, Mattarelli M, Martino S, d'Adda di Fagagna F, Rossi C, Lucioni M, Tancredi R, Pedrazzoli P, Vecchione A, Petrini C, Ferrari F, Lanzuolo C, Bertalot G, Nader G, Foiani M, Piel M, Cerbino R, Giavazzi F, Tripodo C, Scita G

Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer.

Nat Mater 2023; 644-655. doi: 10.1038/s41563-022-01431-x

Lacombe D, Butler-Smith A, Therasse P, Fumoleau P, Burtles S, Calvert H, Marsoni S, Sessa C, Verweij J

Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.

Cancer Invest 2003; 137-47. doi: 10.1081/cnv-120016408

Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Eur J Cancer 2004; 563-70. doi: 10.1016/j.ejca.2003.11.023

Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G

Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.

J Natl Cancer Inst 2004; 750-8. doi: 10.1093/jnci/djh132

Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

J Clin Oncol 2005; 1867-74. doi: 10.1200/JCO.2005.09.032

%PLACEHOLDER%